Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.

Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, Labrecque J, Lau G, Nelson KL, Patel K, Santucci Z, Wong RS, Skerlj RT, Bridger GJ, Huskens D, Schols D, Fricker SP.

Biochem Pharmacol. 2012 Feb 15;83(4):472-9. doi: 10.1016/j.bcp.2011.11.020.

PMID:
22146583
2.

HIV co-receptors as targets for antiviral therapy.

Schols D.

Curr Top Med Chem. 2004;4(9):883-93. Review.

PMID:
15134547
3.

Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function.

Howard OM, Korte T, Tarasova NI, Grimm M, Turpin JA, Rice WG, Michejda CJ, Blumenthal R, Oppenheim JJ.

J Leukoc Biol. 1998 Jul;64(1):6-13. Review.

PMID:
9665268
4.

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.

Seibert C, Sakmar TP.

Curr Pharm Des. 2004;10(17):2041-62. Review.

PMID:
15279544
5.

Structure-based development of antagonists for chemokine receptor CXCR4.

Zhang C, Hou T, Feng Z, Li Y.

Curr Comput Aided Drug Des. 2013 Mar;9(1):60-75. Review.

PMID:
22734712
6.

HIV-1 tropism.

Iwamoto A, Hosoya N, Kawana-Tachikawa A.

Protein Cell. 2010 Jun;1(6):510-3. doi: 10.1007/s13238-010-0066-2. Review. No abstract available.

7.

Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Choi WT, Yang Y, Xu Y, An J.

Curr Top Med Chem. 2014;14(13):1574-89. Review.

8.

Rational design of HIV-1 entry inhibitors.

Debnath AK.

Methods Mol Biol. 2013;993:185-204. doi: 10.1007/978-1-62703-342-8_13. Review.

PMID:
23568472
9.

Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Choi WT, Duggineni S, Xu Y, Huang Z, An J.

J Med Chem. 2012 Feb 9;55(3):977-94. doi: 10.1021/jm200568c. Review. No abstract available.

Supplemental Content

Support Center